2. Academic Validation
  3. Rapamycin analogs with reduced systemic exposure

Rapamycin analogs with reduced systemic exposure

  • Bioorg Med Chem Lett. 2005 Dec 1;15(23):5340-3. doi: 10.1016/j.bmcl.2005.06.106.
Rolf Wagner 1,  Karl W Mollison,  Luping Liu,  Cynthia L Henry,  Teresa A Rosenberg,  Nwe Bamaung,  Noah Tu,  Paul E Wiedeman,  Yatsun Or,  Jay R Luly,  Benjamin C Lane,  James Trevillyan,  Yung-Wu Chen,  Thomas Fey,  Gin Hsieh,  Kennan Marsh,  Merrill Nuss,  Peer B Jacobson,  Denise Wilcox,  Richard P Carlson,  George W Carter,  Stevan W Djuric
Affiliations

Affiliation

  • 1 Abbott Laboratories, Global Pharmaceutical Research and Development, Abbott Park, IL 60064, USA. rolf.wagner@abbott.com
PMID: 16185865 DOI: 10.1016/j.bmcl.2005.06.106
Abstract

The synthesis and biological activities of rapamycin (I) analogs modified at the C-40 position are reported. Emphasis placed on compounds that potentially have an improved safety profile on account of their shorter in vivo half-life when compared with rapamycin.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z